Log in to search using one of your social media accounts:

 

New data on PM1183 sees a response rate of 36 percent as single agent in patients with SCLC
(Pharmamar) Up to today, there is only one approved therapy, topotecan, in relapsed disease, that offers a response rate of between 17 percent and 24 percent. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2017 Category: Cancer & Oncology Source Type: news

Anti-PD 1 Drug Active in Extensive SCLC (CME/CE)
(MedPage Today) -- Pembrolizumab provided 33% response rate in poor-prognosis disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 24, 2017 Category: Hematology Source Type: news

Study Finds That Proton-Beam Therapy is Safe for Treating an Aggressive Type of Lung Cancer
Proton-beam radiotherapy is safe and appears to be effective in treating some cases of small cell lung cancer (SCLC), an aggressive cancer that accounts for about 10 to 15 percent of all lung cancers, according to a new study published online in the journal Cancer. (Source: University of Maryland School of Medicine News Headlines)
Source: University of Maryland School of Medicine News Headlines - August 10, 2017 Category: Universities & Medical Training Source Type: news

Once-Daily RT Fails to Improve Over Standard in Limited-Stage SCLC
Once-daily RT given concurrently with chemotherapy showed no difference in survival compared with the twice-daily standard in small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news

Proton-Beam Therapy in Limited-Stage SCLC Shows Promising Efficacy
Proton-beam therapy was found to be safe for patients with limited-stage small-cell lung cancer in the first prospective registry study of the therapy, with only a small number of high-grade toxicities. (Source: CancerNetwork)
Source: CancerNetwork - July 10, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Radiation Oncology Source Type: news

Adding Palifosfamide in Extensive-Stage SCLC Did Not Increase Survival
Adding palifosfamide to carboplatin and etoposide failed to improve survival over the latter two agents alone in patients with extensive-stage small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 19, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news

Nivolumab Alone or With Ipilimumab Produced Durable Response in SCLC
Treatment with nivolumab alone and in combination with ipilimumab resulted in durable responses in patients with previously treated small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 16, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Lung Cancer News Source Type: news

G-CSF Use in Small Cell Lung Cancer: New Data'Comforting'G-CSF Use in Small Cell Lung Cancer: New Data'Comforting '
Although patients with SCLC given granulocyte colony-stimulating factors during chemo-radiotherapy had an increased risk for hematologic complications, the drugs can be used safely, say researchers.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 9, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

White blood cell boosting drugs safe during chemo-radiotherapy
New research shows that white blood cell boosting drugs are safe during concurrent chemo-radiotherapy of small cell lung cancer (SCLC). (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 5, 2017 Category: Science Source Type: news

Study shows white blood cell boosting drugs safe during chemo-radiotherapy of lung cancer
(European Society for Medical Oncology) A late breaking subanalysis of the phase III CONVERT trial presented at the European Lung Cancer Conference (ELCC) shows that white blood cell boosting drugs are safe during concurrent chemo-radiotherapy of small cell lung cancer (SCLC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 5, 2017 Category: Global & Universal Source Type: news

Bevacizumab Fails to Boost SCLC Survival (CME/CE)
(MedPage Today) -- PFS but not OS improved by angiogenesis inhibitor (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 26, 2017 Category: Hematology Source Type: news

Medical News Today: Small cell lung cancer: Symptoms, treatment, and outlook
What is small cell lung cancer and what are the causes and associated risk factors? How is SCLC diagnosed and what are the different stages? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 20, 2017 Category: Consumer Health News Tags: Lung Cancer Source Type: news

Prophylactic Cranial Irradiation Improved Survival in Metastatic SCLC
This video examines the results of a retrospective study that compared chemotherapy alone or with prophylactic cranial irradiation in extensive-stage SCLC patients with no brain metastases. (Source: CancerNetwork)
Source: CancerNetwork - March 18, 2017 Category: Cancer & Oncology Authors: Sonam Sharma, MD Tags: Videos Lung Cancer Source Type: news

Prevention and prediction: Understanding how lung cancer progresses
(University of Pennsylvania School of Medicine) Treating the brain with a preventative course of radiation may help small cell lung cancer (SCLC) patients -- whose tumors often spread to their brain -- live longer, according to a new study from researchers in the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania. A separate study revealed that the most commonly-targeted mutation of non-small cell lung cancer (NSCLC) is most likely to result in progression at the primary site. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 16, 2017 Category: Cancer & Oncology Source Type: news

Bevacizumab Combination Improves PFS, but Not OS, in Extensive-Disease SCLC
The addition of bevacizumab to a first-line regimen of cisplatin and etoposide improved progression-free survival in patients with extensive-disease small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 30, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news

Exceptional SCLC Survivors: 5-Year Median Survival Exceptional SCLC Survivors: 5-Year Median Survival
Longer-term survival of patients with extensive small cell lung cancer (SCLC) is associated with comprehensive cisplatin chemotherapy with additional chest and cranial radiation, suggest researchers.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 20, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

G1 Therapeutics and Genentech to evaluate Phase II lung cancer trial of tecentriq and trilaciclib
US-based clinical-stage oncology company G1 Therapeutics has collaborated with Genentech to conduct a Phase II clinical trial of tecentriq and trilaciclib to treat patients with small-cell lung cancer (SCLC) receiving chemotherapy. (Source: Drug Development Technology)
Source: Drug Development Technology - December 7, 2016 Category: Pharmaceuticals Source Type: news

Updated KEYTRUDA ® (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer
Dateline City: KENILWORTH, N.J. Findings in Small Cell Lung Cancer and Malignant Pleural Mesothelioma Show Overall Response Rates of 33.3 Percent and 20.0 Percent, Respectively, in KEYNOTE-028 Long-Term Data Demonstrate Durable Responses in Difficult-to-Treat CancersKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated findings from the phase 1b KEYNOTE-028 study investigating the use of KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, in previously treated patients with advanced small cell lung cancer...
Source: Merck.com - Product News - December 6, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda Lung Cancer MSD NYSE:MRK Source Type: news

Histopathological Transformation to SCLC in NSCLC Tumors Histopathological Transformation to SCLC in NSCLC Tumors
Is it time to re-biopsy? Deterioration during targeted therapy may indicate transformation of NSCLC to SCLC.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 1, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Blood test could predict best treatment for lung cancer
A blood test could predict how well small-cell lung cancer (SCLC) patients will respond to treatment, according to new research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 21, 2016 Category: Science Source Type: news

Pearls from: Hossein Borghaei, DO
(MedPage Today) -- Thoracic oncologist discusses turning the corner in SCLC therapies (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - September 29, 2016 Category: Primary Care Source Type: news

Yervoy Plus Chemo Disappoints in SCLC (CME/CE)
(MedPage Today) -- Combo treatment did not prolong survival versus chemo alone in extensive-stage disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 7, 2016 Category: Hematology Source Type: news

PharmaMar begins Phase III ATLANTIS trial of PM1183 combined with doxorubicin to treat SCLC
Spanish biopharmaceutical company PharmaMar has initiated the pivotal Phase III ATLANTIS study of PM1183 combined with doxorubicin versus topotecan or the combination VCR (cyclophosphamide, adriamicine (doxorubicin) and vincristine) to treat small-ce … (Source: Drug Development Technology)
Source: Drug Development Technology - August 2, 2016 Category: Pharmaceuticals Source Type: news

PharmaMar initiates a pivotal Phase III ATLANTIS study with PM1183 in SCLC
(Pharmamar) PharmaMar today announced the start of a pivotal Phase III ATLANTIS study evaluating efficacy and safety of PM1183 in combination with doxorubicin versus topotecan or the combination VCR in patients with small cell lung cancer after the failure of one prior platinum-containing line. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 2, 2016 Category: Cancer & Oncology Source Type: news

Two-drug immunotherapy deemed safe for lung cancer patients, Moffitt study shows
(H. Lee Moffitt Cancer Center & Research Institute) A new Moffitt Cancer Center study being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and published in The Lancet Oncology shows that utilizing the immunotherapeutic agents nivolumab and ipilimumab could lead to more effective treatment options for SCLC patients who fail initial therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2016 Category: Cancer & Oncology Source Type: news

AbbVie to take over Stemcentrx and its Rova-T therapy for SCLC for $5.8bn
US-based biopharmaceutical company AbbVie will acquire biotechnology company Stemcentrx for nearly $5.8bn. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 2, 2016 Category: Pharmaceuticals Source Type: news

Second-line Therapy for SCLC: Potential Role of CTCsSecond-line Therapy for SCLC: Potential Role of CTCs
Do circulating tumor cells in recurrent SCLC have chemosensitivity? Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 21, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

G1 Therapeutics begins G1T28’s two Phase Ib / IIa trials for SCLC
Clinical-stage pharmaceutical firm G1 Therapeutics has commenced two Phase Ib / IIa trials of the CDK4 / 6 inhibitor G1T28 in patients with small-cell lung cancer (SCLC). (Source: Drug Development Technology)
Source: Drug Development Technology - August 11, 2015 Category: Pharmaceuticals Source Type: news

Findings Presented at 2015 ASCO Annual Meeting Add to Breadth of KEYTRUDA® (pembrolizumab) Data; Anti-Tumor Activity Now Demonstrated in 13 Different Tumor Types
Dateline City: KENILWORTH, N.J. New Data Presented at ASCO in Multiple, Difficult-to-Treat Cancers, including Small Cell Lung, Esophageal and Ovarian Cancers Registrational Studies for KEYTRUDA Ongoing in Eight Different Tumor Types KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in multiple, difficult-to-treat cancers, inclu...
Source: Merck.com - Research and Development News - June 1, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news

PharmaMar will start a Phase III study of PM1183 plus doxorubicin in relapsed SCLC
(Pharmamar) Data from a Phase 1b study demonstrate a marked anti-tumor activity in patients with relapsed SCLC treated with PM01183 in combination with doxorubicin, which was in general well-tolerated and induced several complete responses. PharmaMar will start a pivotal Phase 3 trial to compare PM01183 plus doxorubicin against topotecan in relapsed SCLC as second-line therapy, the only drug approved by the EMA and the FDA for this indication (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 13, 2015 Category: Biology Source Type: news

CytRx begins Phase IIb trial of aldoxorubicin to treat lung cancer
US-based biopharmaceutical research and development firm CytRx, has started a global Phase IIb clinical trial assessing aldoxorubicin compared to topotecan in patients with extensive-stage small cell lung cancer (SCLC,) who have relapsed or were refr… (Source: Drug Development Technology)
Source: Drug Development Technology - October 1, 2014 Category: Pharmaceuticals Source Type: news

Consistent Genomic Alterations in SCLCConsistent Genomic Alterations in SCLC
Can high-sensitivity genomic profiling discover actionable genomic alterations and potential new routes to targeted therapies in patients with SCLC? Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 23, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Mixed Results With Thoracic RT in Advanced SCLC
SAN FRANCISCO (MedPage Today) -- Thoracic radiotherapy failed to improve 1-year survival in patients with advanced small cell lung cancer, but 2-year survival did improve significantly, a randomized trial showed. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 15, 2014 Category: Hematology Source Type: news

Oncology Experts Mark 20 Years of Evidence-Based Decision-Making in Small Cell Lung Cancer
NCCN has published the 20th annual edition of its NCCN Guidelines® for Small Cell Lung Cancer, marking the first 20th edition of the eight original NCCN Guidelines published in November 1996. FORT WASHINGTON, PA - The National Comprehensive Cancer Network® (NCCN®) has published its 20th annual edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer (SCLC). One of the eight original NCCN Guidelines®, the NCCN Guidelines for SCLC was initially ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - September 6, 2014 Category: Cancer & Oncology Source Type: news

Mixed Results in NSCLC, SCLC Trials (CME/CE)
(MedPage Today) -- Two-thirds of patients with recurrent, mutated non-small cell lung cancer responded to an investigational agent that selectively targets mutant cells and spares normal ones, results of a preliminary trial showed. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 2, 2014 Category: Geriatrics Source Type: news

Novel SCLC tumour suppressor gene discovered
Inactivation of the MYC-associated factor X gene, MAX, may play a significant role in the development of small-cell lung cancer, scientists believe. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 26, 2014 Category: Cancer & Oncology Source Type: news

Novel SCLC tumour suppressor gene discovered
Inactivation of the MYC-associated factor X gene, MAX, may play a significant role in the development of small-cell lung cancer, scientists believe. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - February 26, 2014 Category: Cancer & Oncology Source Type: news

Etoposide plus cisplatin remains best for limited-stage SCLC
Etoposide plus cisplatin, given alongside accelerated hyperfractionated thoracic radiotherapy, remains the gold standard regimen for patients with limited-stage small-cell lung cancer, Japanese researchers say. (Source: MedWire News - Respiratory)
Source: MedWire News - Respiratory - January 23, 2014 Category: Respiratory Medicine Source Type: news

Etoposide plus cisplatin remains best for limited-stage SCLC
Etoposide plus cisplatin, given alongside accelerated hyperfractionated thoracic radiotherapy, remains the gold standard regimen for patients with limited-stage small-cell lung cancer, Japanese researchers say. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 23, 2014 Category: Cancer & Oncology Source Type: news

Etoposide plus cisplatin remains best for limited-stage SCLC
Etoposide plus cisplatin, given alongside accelerated hyperfractionated thoracic radiotherapy, remains the gold standard regimen for patients with limited-stage small-cell lung cancer, Japanese researchers say. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - January 23, 2014 Category: Cancer & Oncology Source Type: news

Four Cycles of Etoposide Plus Cisplatin for Limited SCLCFour Cycles of Etoposide Plus Cisplatin for Limited SCLC
For limited-stage small-cell lung cancer, 4 cycles of etoposide plus cisplatin and accelerated hyperfractionated thoracic radiotherapy should remain the standard of care, research suggests. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 26, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

The Use of Mouse Models for Lung Cancer Chemoprevention Studies
Mouse lung tumor models are widely used in lung cancer chemopreventive studies. Lung cancer is a heterogeneous disease histologically classified as small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC), which is usually divided into adenocarcinoma, squamous cell carcinoma (SCC), and large cell carcinoma. In order to illustrate the power of the mouse model in preclinical lung cancer investigations, comprehensive instructions for the selection of mice, genotyping, and induction of lung tumors (e.g., adenoma/adenocarcinoma, lung SCC, and SCLC) in mice are provided. We have described in detail the histolog...
Source: Springer protocols feed by Pharmacology/Toxicology - November 27, 2013 Category: Drugs & Pharmacology Source Type: news

Simple blood test for sub-type specific lung cancer diagnosis
Lung cancer is the leading cause of cancer specific death worldwide. 85% lung cancers are non-small cell lung cancers (NSCLC) while remaining are small cell lung cancers (SCLC). Although X-Ray and CT scan remain the main non-invasive diagnosis strategy, the painful lung tissue biopsy is essential for confirmation and staging of the disease... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 12, 2013 Category: Consumer Health News Tags: Lung Cancer Source Type: news

Cornerstone begins Phase II trial of lung cancer drug
US-based Cornerstone Pharmaceuticals has started a Phase II clinical trial of its lead Altered Energy Metabolism Directed (AEMD) drug candidate, CPI-613 for the treatment of patients with relapsed or refractory small cell lung cancer (SCLC). (Source: Drug Development Technology)
Source: Drug Development Technology - October 28, 2013 Category: Pharmaceuticals Source Type: news

The PFP/RAG2 Double-Knockout Mouse in Metastasis Research: Small-Cell Lung Cancer and Prostate Cancer
Patients with small-cell lung cancer (SCLC) and prostate cancer (PCa) as well as other solid tumors may have micro- or macro-metastatic spread at an early stage of the disease. SCLC and PCa xenograft transfer models in immunodeficient mice fail to model this metastatic spread in vivo. In both tumor types the depletion of NK cells found in immunodeficient mice results in an increased number of spontaneous metastases, mirroring the clinical situation where NK cell activity in patients is related to metastatic spread of the disease. As a result NK cell activity directly influences treatment options and mortality. Newly develo...
Source: Springer protocols feed by Cancer Research - October 8, 2013 Category: Cancer & Oncology Source Type: news

Small-Cell Lung Cancer (SCLC) Cell Adhesion on E- and P-Selectin Under Physiological Flow Conditions
Hematogenous metastasis is still a poorly understood phenomenon. The rate-limiting step within the metastatic cascade is not yet clear although it may be estimated that the extravasation of circulating tumor cells is a step of crucial importance, as most tumor cells that are shed into circulation undergo apoptosis. The process of extravasation includes a cascade of consecutive steps, starting with adhesion of tumor cells circulating in the bloodstream to endothelial cells, mimicking leukocyte adhesion and transmigration. Endothelial cell selectin–leukocyte glycan interaction occurs when leukocytes adhere to endotheli...
Source: Springer protocols feed by Cancer Research - October 8, 2013 Category: Cancer & Oncology Source Type: news

Repurposed antidepressants have potential to treat small-cell lung cancer
A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small-cell lung cancer (SCLC), according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research. Based on data generated using bioinformatics, two drugs approved by the U.S. Food and Drug Administration (FDA) to treat symptoms of depression were tested on SCLC cells and animal models. Both antidepressants were found to induce SCLC cell death... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 27, 2013 Category: Consumer Health News Tags: Lung Cancer Source Type: news

MicroRNAs Regulate Small-Cell Lung Cancer Bone Metastasis
Researchers have identified a novel pathway that promotes bone metastasis of small-cell lung cancer (SCLC). The study is in mice, but points to a potential target that could be exploited to control or prevent metastatic disease. (Source: Cancer Network)
Source: Cancer Network - September 17, 2013 Category: Cancer & Oncology Source Type: news

Chemotherapy helps elderly patients with small cell lung cancer
Although numerous randomized clinical trials have demonstrated a benefit of chemotherapy for patients with small-cell lung cancer (SCLC), these trials have predominantly compared different chemotherapy regimens rather than comparing chemotherapy to best supportive care. Some of them included chest radiation or prophylactic cranial irradiation. Moreover, many trials excluded elderly patients. A recent retrospective study looked at the benefit of chemotherapy on survival of elderly patients with SCLC in the community... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 6, 2013 Category: Consumer Health News Tags: Lung Cancer Source Type: news

Prophylactic cranial irradiation beneficial in elderly SCLC patients
Prophylactic cranial irradiation improves survival in elderly patients with limited-stage small-cell lung cancer, analysis of US epidemiologic data indicates. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - September 6, 2013 Category: Cancer & Oncology Source Type: news